Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on Active Substances and Nitrosamine Impurities

On 26 July 2022, the EMA published a concept paper to start the process for the revision of the Guideline on the chemistry of active substances. The document dates from 2016 and does not consider the nitrosamine issue that has developed in recent years.

The critical need to revise and update this important guideline was identified when the "Lessons learnt report" on impurities in sartan medicines was compiled.

What can be expected in terms of content?
Recommendations for the prevention, risk reduction and control of N-nitrosamines, but also for other "contaminants of concern" (CoC) and potent toxins will be included. Also to be tackled are

  • Strategies for process development
  • The subject areas of raw materials, starting materials and intermediate products and their potential contamination risk
  • The use of recycled materials
  • Specific control options for nitrosamines

The EMA Quality Working Party (QWP) has appointed two rapporteurs as well as experts from different Member States with expertise in this field to the drafting group. The group will be supported by an observer from the European Directorate for Quality of Medicines (EDQM), who will work closely with the QWP expert group on nitrosamines.

What is the schedule?

The concept paper will be available for comments until 31 October 2022. Following this, a draft document will be prepared, which will then be released for comments for six months.


Source:

EMA: Concept Paper on the revision of the guideline on the chemistry of active substances
EMA: Guideline on the chemistry of active substances

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: New Q&A on Product Lifecycle Management (PLCM)

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.
Read more
EMA: New Q&A for Co-Processed Excipients

EMA: New Q&A for Co-Processed Excipients

The EMA has published new Questions & Answers on co-processed excipients (CoPEs) used in solid oral dosage forms, introducing a harmonised, risk-based regulatory approach applicable to human and veterinary medicines.

Read more
What is the Data Lifecycle?

What is the Data Lifecycle?

Here's the answer:
Read more
GMP Regulations Report 2025

GMP Regulations Report 2025

What do the regulatory developments mean for your professional environment? Which requirements have a direct impact on your day-to-day work, and where is there an urgent need for action? Our GMP Regulations Report 2025 provides a clear structure, practical explanations, and the most important regulatory developments of 2025 – concise, well-organized, and relevant.
Read more
EU: Parliament Approves Regulation Proposal on Critical Medicines

EU: Parliament Approves Regulation Proposal on Critical Medicines

The European Parliament has approved regulatory measures aimed at strengthening the availability and supply of critical medicines in the EU.
Read more
What is a gas?

What is a gas?

You can view the answer here:
Read more
Previous
Next